Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of complement factor 5, or C5, for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. The company also has discovery-stage programs that are focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was incorporated in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporation operates as a subsidiary of Rallybio Holdings, LLC.
IPO Year: 2021
Exchange: NASDAQ
Website: rallybio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2024 | Overweight → Neutral | JP Morgan | |
| 2/7/2024 | $7.00 → $1.50 | Buy → Hold | Jefferies |
| 4/17/2023 | $18.00 | Buy | H.C. Wainwright |
| 4/10/2023 | $17.00 | Outperform | Wedbush |
| 12/9/2022 | $21.00 | Overweight | JP Morgan |
| 2/22/2022 | $32.00 | Mkt Outperform | JMP Securities |
| 8/23/2021 | $40.00 | Outperform | Evercore ISI Group |
| 8/23/2021 | Outperform | Cowen | |
| 8/23/2021 | $20.00 | Buy | Jefferies |
— Screening is Now Underway to Identify Pregnant Women at Higher Risk for HPA-1a Alloimmunization and FNAIT — Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of its Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Screening is now underway to identify the first (sentinel) pregnant woman for enrollment in the Phase 2 trial. "The initiation of screening in the RLYB212 Phase 2 trial is a significant milestone," s
— CTA Approvals Received for RLYB212 Phase 2 Clinical Trial; On Track to Initiate Screening in 4Q 2024 — — $75.1 Million in Cash, Cash Equivalents, and Marketable Securities as of September 30, 2024 Provides Runway into Mid-2026 — Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported third quarter financial results for the period ended September 30, 2024, and provided an update on recent company developments. "Advancing RLYB212 into a Phase 2 trial marks a significant achievement for Rallybio. With clinical trial application (CTA) approvals in-han
— First Ever Trial in Pregnant Women at Higher Risk of Alloimmunization and FNAIT — — Screening in the Phase 2 Clinical Trial On Track to Initiate in 4Q 2024 — Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the approval of its clinical trial applications (CTAs) for a Phase 2 clinical trial of RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). With these approvals from the European Medicines Agency (EMA) and the United Kingdom's Medicines and Healthcare products Re
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that nonclinical data demonstrating ENPP1 inhibition as a therapeutic approach for the treatment of patients with hypophosphatasia (HPP) was presented at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. ASBMR is being held September 27 – 30, 2024 in Toronto, Canada. "From my team's earlier work published in 2002 and 2005, we knew that ENPP1 could be a targetable molecule to modulate TNAP's all-important substrate PPi. I am delighted that we have now been able to de
– Results Indicate that FNAIT Risk is More Prevalent Than Previously Estimated – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that full data from an epidemiological analysis quantifying the proportion of women across diverse populations at higher risk of a fetal and neonatal alloimmune thrombocytopenia (FNAIT)-impacted pregnancy will be presented at the American Society of Human Genetics (ASHG) 2024 Annual Meeting to be held November 5 – 9, 2024 in Denver, CO. "With our Phase 2 trial of RLYB212 in pregnant women at higher risk for HPA-1a
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that full data from an epidemiological analysis quantifying the proportion of women across diverse populations at higher risk of a fetal and neonatal alloimmune thrombocytopenia (FNAIT)-impacted pregnancy will be presented at the NORD Rare Diseases & Orphan Products Breakthrough Summit to be held October 20 – 22, 2024 in Washington DC. "Consistent with the NORD Summit theme of ‘Equitable Access to Innovation,' our epidemiological analysis is particularly pertinent, providing the first clear evid
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that Fierce Life Sciences and Fierce Healthcare has named Rallybio an Innovation Honoree as part of the 2024 Fierce 50 list. The Fierce 50 showcases 50 individuals and companies driving advancements in medicine, fostering innovation, and shaping the future of biopharma and healthcare. "The annual Fierce 50 special report highlights individuals and companies that are driving progress in the pharmaceutical, healthcare and biotechnology industries," said Ayla Ellison, Editor-in-Chief of Fierce Life
– Study Demonstrates that RLYB212 Rapidly Clears HPA-1a Positive Platelets, an Essential Step in Preventing Alloimmunization and FNAIT – – Rallybio On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk for FNAIT in 4Q 2024 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that data from the Phase 1 proof-of-concept study of RLYB212, a novel monoclonal anti-HPA-1a antibody in development for the prevention of maternal alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT), were pu
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced its participation in the following upcoming investor conferences: 2024 Wells Fargo Healthcare Conference in Everett, MA on Thursday, September 5, 2024. Stephen Uden, M.D., Chief Executive Officer, will participate in a fireside chat at 3:45 p.m. ET. H.C. Wainwright 26th Annual Global Investment Conference in New York, NY on Tuesday, September 10, 2024. Dr. Uden will present a corporate overview at 11:00 a.m. ET. Live webcasts of the Wells Fargo fireside chat and H.C. Wainwright presentat
– On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 4Q 2024 – – $88.6 Million in Cash, Cash Equivalents, and Marketable Securities as of June 30, 2024 Provides Runway into Mid-2026 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported second quarter financial results for the period ended June 30, 2024, and provided an update on recent company developments. "We are working expeditiously towards the initiation of our Phase 2 dose confirmation trial for RLYB212 in pregnant women at higher r
10-Q - Rallybio Corp (0001739410) (Filer)
8-K - Rallybio Corp (0001739410) (Filer)
8-K - Rallybio Corp (0001739410) (Filer)
10-Q - Rallybio Corp (0001739410) (Filer)
8-K - Rallybio Corp (0001739410) (Filer)
8-K - Rallybio Corp (0001739410) (Filer)
8-K - Rallybio Corp (0001739410) (Filer)
EFFECT - Rallybio Corp (0001739410) (Filer)
S-3 - Rallybio Corp (0001739410) (Filer)
10-Q - Rallybio Corp (0001739410) (Filer)
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis -- -- Company Announces Extension of Runway to 3Q 2025 As Part of Portfolio Prioritization -- -- Conference Call and Webcast Today at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated disea
SC 13G/A - Rallybio Corp (0001739410) (Subject)
SC 13G - Rallybio Corp (0001739410) (Subject)
SC 13G/A - Rallybio Corp (0001739410) (Subject)
SC 13G/A - Rallybio Corp (0001739410) (Subject)
SC 13D/A - Rallybio Corp (0001739410) (Subject)
SC 13G/A - Rallybio Corp (0001739410) (Subject)
SC 13G/A - Rallybio Corp (0001739410) (Subject)
SC 13G/A - Rallybio Corp (0001739410) (Subject)
SC 13G/A - Rallybio Corp (0001739410) (Subject)
SC 13G/A - Rallybio Corp (0001739410) (Subject)
-- Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio's President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1, 2023. Dr. Uden will remain President and will also be appointed to Rallybio's Board of Directors. The Company does not expect to hire a replacement for Dr. Uden's current role. He will succeed Mart
-- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025 -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company's Chief Financial Officer (CFO), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio's Co-Founder and CFO. The company announced Mr. Fryer's departure in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer will depart the company on February 15, 2023. Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment ban
-- Emerging data from Phase 1b study of RLYB212 shows rapid and complete elimination of transfused HPA-1a positive platelets -- -- Phase 1 study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected for the 30 mg dose in the 4Q 2022 -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent program and corporate developments. "We continue to progress our pipeline toward planned upcoming milestones. We are pleased
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has appointed Wendy K. Chung, M.D., Ph.D., to its Board of Directors. "Wendy is a tremendous addition to our Board of Directors. Her extensive clinical experience and deep scientific expertise will be a valued asset as we continue to advance our current product portfolio as well as bring additional candidates into our pipeline. We look forward to learning from her expertise and insights," said Martin Mackay, Ph.D., Chairman and Chief Executive Officer at Rallybi
--Company initiates an external search for its next Chief Financial Officer-- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jeffrey Fryer, CPA, will retire from his position as Chief Financial Officer (CFO). Mr. Fryer will continue to serve as Rallybio's CFO until a new CFO has been appointed and will retire from the Company following a transition period. Rallybio has initiated an external search to identify its next CFO. "On behalf of the Board of Directors, co-founder Steve Uden, and the Rallybio team, I wo
– First Reported Large-Scale Analysis of FNAIT Risk Across Broad Population of Diverse Ancestries –– Topline Results Suggest a Significant Increase in the Number of Pregnancies at Higher Risk for FNAIT Annually and the RLYB212 Addressable Market –– Rallybio On Track to Initiate RLYB212 Phase 2 Dose Confirmation Study in Pregnant Women at Higher Risk for FNAIT in 2H 2024 –Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported topline results from an epidemiological analysis of large genomic datasets evaluating the frequency of fetal and neonatal alloimm
Gainers Venus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. The market value of their outstanding shares is at $9.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares increased by 8.58% to $2.15. The market value of their outstanding shares is at $3.1 million. Applied DNA Sciences (NASDAQ:APDN) stock moved upwards by 8.27% to $0.59. The market value of their outstanding shares is at $6.0 million. Kiora Pharmaceuticals (NASDAQ:KPRX) shares rose 5.0% to $0.45. The market value of their outstanding shares is at $11.9 million. Fractyl Health (NASDAQ:GUTS) shares moved upwards by 4.94% to $6.79. The market value of their outstanding shares is at
JP Morgan analyst Anupam Rama downgrades Rallybio (NASDAQ:RLYB) from Overweight to Neutral.
-SEC Filing
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Rallybio (NASDAQ:RLYB) with a Buy and maintains $9 price target.
Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.50) by 6 percent. This is a 9.3 percent decrease over losses of $(0.43) per share from the same period last year.
JMP Securities analyst Jonathan Wolleben reiterates Rallybio (NASDAQ:RLYB) with a Market Outperform and maintains $8 price target.
JMP Securities analyst Jonathan Wolleben reiterates Rallybio (NASDAQ:RLYB) with a Market Outperform and maintains $8 price target.
- Data Support HPA-1a Negative Frequency of More than 2% in Nearly 200,000 Screened Pregnant Women -- Among HPA-1a Negative Pregnant Women, Approximately 33% are at Higher Risk for Alloimmunization -Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the presentation of results from a fetal and neonatal alloimmune thrombocytopenia (FNAIT) systematic literature review and meta-analysis at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting, which is taking place in New Orleans, LA. The results of this research
Gainers Longeveron (NASDAQ:LGVN) stock moved upwards by 44.4% to $2.44 during Monday's regular session. The market value of their outstanding shares is at $7.7 million. Mobile-health Network (NASDAQ:MNDR) shares rose 35.53% to $20.33. The company's market cap stands at $691.2 million. Jaguar Health (NASDAQ:JAGX) shares moved upwards by 31.89% to $0.12. The company's market cap stands at $32.8 million. Soligenix (NASDAQ:SNGX) stock increased by 30.35% to $0.5. The market value of their outstanding shares is at $5.2 million. ProKidney (NASDAQ:PROK) stock increased by 26.33% to $2.21. The company's market cap stands at $136.2 million. Organovo Holdings (NASDAQ:ONVO) shares moved upwards b
JP Morgan downgraded Rallybio from Overweight to Neutral
Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously
H.C. Wainwright initiated coverage of Rallybio with a rating of Buy and set a new price target of $18.00
Wedbush initiated coverage of Rallybio with a rating of Outperform and set a new price target of $17.00
JP Morgan initiated coverage of Rallybio with a rating of Overweight and set a new price target of $21.00
JMP Securities initiated coverage of Rallybio with a rating of Mkt Outperform and set a new price target of $32.00
Evercore ISI Group initiated coverage of Rallybio with a rating of Outperform and set a new price target of $40.00
Cowen initiated coverage of Rallybio with a rating of Outperform
Jefferies initiated coverage of Rallybio with a rating of Buy and set a new price target of $20.00